Abstracts tagged "Polymyalgia Rheumatica (PMR)"

Abstract Number: 2150 • ACR Convergence 2024
Understanding Unmet Needs and Quality of Life Impact of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) Using Social Media: A Patient and Caregiver Perspective
Pallavi Arun¹, Nikita Parashar¹, Sakshi Sharma¹, Kanika Arora¹, Vandana Padmanabhan¹ and Alvaro Arjona², ¹Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ²Novartis Farmaceutica, S.A., Madrid, Madrid, Spain
Background/Purpose: Analyzing social media conversations of patients (pts) and caregivers can be useful to understand the real-world perspectives thereby improving quality of healthcare.1 GCA and…
Abstract Number: 0276 • ACR Convergence 2024
Exploring the Prevalence of Crowned Dens Syndrome in a Polymyalgia Rheumatica Veterans Affairs Patient Cohort
Marlene Marte Furment¹, Binod Kc¹, Bhavya Poudyal¹, Aakritee Sharma Subedi², Mahnoor Sherazi³, Jihad Ben Gabr¹, Shveta Trikha⁴, Brian Cooney⁵ and Fatme Allam⁵, ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY Upstate University Hospital, Syracuse, ³State University of New York, Syracuse, NY, ⁴Syracuse VA Medical Center, Syracuse, ⁵Syracuse VA Medical Center, Syracuse, NY
Background/Purpose: Crowned Dens (CD) is the radiological finding of calcium pyrophosphate dihydrate (CPPD) crystal deposition in the cruciform and alar ligaments giving the appearance of…
Abstract Number: 0975 • ACR Convergence 2024
Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica
Sebastian E. Sattui¹, FRANK HARTMUT DR. BUTTGEREIT², Merav Lidar³, Kerri Ford⁴, Stefano Fiore⁵, Lita Araujo⁴, Timothy Beukelman⁶, Fenglong Xie⁷ and Jeffrey Curtis⁸, ¹University of Pittsburgh, Pittsburgh, PA, ²Charité University Medicine Berlin, Berlin, Germany, ³Rheumatology Unit, Sheba Medical Center, Tel Hashomer, Israel, ⁴Sanofi, Cambridge, MA, ⁵Sanofi, Bridgewater, NJ, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: PMR, a common inflammatory rheumatic disease in older adults, is primarily treated with glucocorticoids (GC). A high comorbidity burden in PMR may increase the…
Abstract Number: 2508 • ACR Convergence 2024
The Impact of Lipid Profile Parameters on the Incidence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis Patients: A Single-arm Meta-Analysis
Nouman Shafique¹, Ali Raza Khan², Abdul Qadeer², zaigham Shaukat² and Rabia Iqbal², ¹AdventHealth Orlando, Orlando, FL, ²Nishtar Medical University, Multan, Punjab, Pakistan
Background/Purpose: Cardiovascular diseases (CVD) are a significant cause of morbidity and mortality among patients with rheumatoid arthritis (RA), accounting for nearly 40% of their mortality.…
Abstract Number: 1054 • ACR Convergence 2023
Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT
David Liew¹, Aurora Poon¹, Christopher McMaster², Russell Buchanan¹, Victor Yang¹, Andrew Scott¹ and Claire Owen³, ¹Austin Health, Heidelberg, Australia, ²Austin Health, Pascoe Vale South, Australia, ³Austin Health, Malvern East, Australia
Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to…
Abstract Number: 1098 • ACR Convergence 2023
Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Kelly Tran¹, Ellen Ann Sockman¹, Rachel Salyer¹, Megan Young¹, Aisha Abbasi¹ and Devanshu Verma², ¹West Virginia University Hospital, Morgantown, WV, ²West Virginia University, Morgantown, WV
Background/Purpose: Osteoporosis is a medical condition associated with decreased bone mass and bone architecture, which increases incidence of fragility fractures(4). It is associated with 1.5…
Abstract Number: 1133 • ACR Convergence 2023
Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center
William Rigby¹, Todd Mackenzie², Emily Campbell¹, Joshua Skydel³, Bryan Savage¹, Monica Dimambro² and Vivekanand Tiwari¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth College, Hanover, NH, ³Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Polymyalgia rheumatica (PMR) treatment is primarily based on long-term corticosteroids, which results in significant toxicities. Studies1,2 have shown that patients with PMR are exposed…
Abstract Number: 1201 • ACR Convergence 2023
Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², David Kane³ and Richard Conway⁴, ¹St James's Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Ireland, ³Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland
Background/Purpose: Frailty is an increasingly important construct in the field of rheumatology, aiding the identification of individuals with increased vulnerability to accelerated clinical decline and…
Abstract Number: 1565 • ACR Convergence 2023
Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴ and David Kane⁵, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: It has been reported that up to a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It is currently…
Abstract Number: 1566 • ACR Convergence 2023
Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica
Christine Xu¹, Ying Liu¹, Jennifer Sloane², Remco Diab³, Hubert van Hoogstraten¹, Hisham Abdallah⁴, Sreeraj Macha¹ and Bhaskar Dasgupta⁵, ¹Sanofi, Bridgewater, NJ, ²Sanofi, Cambridge, MA, ³Sanofi, Rotkreuz, Switzerland, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Anglia Ruskin University, East Anglia, United Kingdom
Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to the membrane-bound and soluble IL-6 receptor-α subunit (IL-6Rα). Sarilumab is now approved for both rheumatoid arthritis (RA)…
Abstract Number: 1649 • ACR Convergence 2023
Follow-up Ultrasound Examination in Patients with Newly Diagnosed Giant Cell Arteritis
Lara Clarissa Burg¹, Christian Dejaco², Pantelis Karakostas³, Charlotte Behning⁴, Peter Brossart¹ and Valentin Sebastian Schäfer³, ¹University Hospital of Bonn, Bonn, Germany, ²Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ³Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ⁴Institute of Medical Biometry, Informatics and Epidemiology, Medical Faculty, University of Bonn, Bonn, Germany
Background/Purpose: In recent years, ultrasound has become a standard tool in the diagnosis of giant cell arteritis (GCA). Typical findings are increased intima media thickness…
Abstract Number: 0027 • ACR Convergence 2023
Association of HLA-DRB1 and ANKRD55/IL6ST Regions with Polymyalgia Rheumatica Diagnosis: A Genome Wide Association Study from UK Biobank and FinnGen
Mehmet Hocaoglu¹, Jamal Mikdashi², James Perry² and Charles Hong², ¹University of Maryland School of Medicine, Pittsburgh, PA, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The existing literature on the genetics of polymyalgia rheumatica (PMR) is limited to candidate gene studies with small sample sizes. There is a need…
Abstract Number: 1869 • ACR Convergence 2023
FDG-PET/CT for Diagnosing Polymyalgia Rheumatica Before, During and After a Short-term Prednisolone Cessation – a Prospective Study of 101 Patients
Andreas Wiggers Nielsen¹, Ib Tønder Hansen², Berit Dalsgaard Nielsen³, Søren Geill Kjær⁴, Jesper Blegvad-Nissen⁴, Christian Møller Sørensen³, Ellen-Margrethe Hauge¹, Lars Christian Gormsen² and Kresten Krarup Keller¹, ¹Aarhus University Hospital, Aarhus, Denmark, ²Aarhus University Hospital, Aarhus N, Denmark, ³Department of Internal Medicine, Horsens, Denmark, ⁴Diagnostic Centre, Silkeborg, Denmark
Background/Purpose: Polymyalgia rheumatica (PMR) can be challenging to diagnose since other diseases may present with similar symptoms. As a result, a significant number of patients…
Abstract Number: 0267 • ACR Convergence 2023
Variations in Approach to the Diagnosis and Management of Polymyalgia Rheumatica Among Australian Rheumatologists
Victor Yang¹, Jem Ninan², David Liew¹, Helen Keen³, Catherine Hill⁴ and Jessica Leung⁵, ¹Austin Health, Heidelberg, Australia, ²University of Adelaide, Adelaide, Australia, ³University of Western Australia, Daglish, Australia, ⁴The Queen Elizabeth Hospital, Woodville, Australia, ⁵Austin Health, Preston, Australia
Background/Purpose: Polymyalgia rheumatica (PMR) is the second-most common inflammatory rheumatic disease but there remains variation amongst rheumatologists in approaches to diagnosis and management. This study…
Abstract Number: 1878 • ACR Convergence 2023
MRI-determined Intramuscular Fat Changes During Oral Glucocorticoid Treatment: Findings from a Feasibility Study
Thurkka Rajeswaran¹, Emma Harris², hannah Mathieson¹, John Biglands³, Paul Stewart¹, Ai Lyn Tan¹ and Sarah Mackie⁴, ¹University of Leeds, Leeds, United Kingdom, ²The Open University, Milton Keynes, United Kingdom, ³NIHR Leeds Biomedical Research Centre and Medical Physics and Engineering , Leeds Teaching Hospitals NHS Trust Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Oral glucocorticoid therapy has many adverse effects including insulin resistance and myopathy. Long-term glucocorticoid therapy causes a "sarcopenic obesity" phenotype of adiposity with muscle…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].